Beyond Pills: Integrating the Microbiome Into the Future of Drug Development

As our understanding of the microbiome deepens, a new horizon is opening beyond classic drug-centric approaches. This session explores how integrating microbiome insights can transform drug development and therapeutic strategies, enabling more precise, effective and sustainable healthcare solutions.

Themes :

• Drug–microbiome interactions (pharmacomicrobiomics): Understanding how the microbiome influences drug metabolism, efficacy and safety.
• Combination strategies: Pairing conventional drugs with microbiome modulators to enhance outcomes or mitigate side effects.
• Microbiome-based therapies: From fecal microbiota transplants (FMT) to live biotherapeutics and next-generation engineered strains.
• The data and technology stack: What infrastructure is needed to integrate microbiome data into R&D pipelines and clinical decision-making?

Participants should leave with a clear picture of how to move from molecule-centered development to systems-level approaches that embrace the microbiome as a key therapeutic partner.